We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cardium Therapeutics Announces Addition of Vice President
News

Cardium Therapeutics Announces Addition of Vice President

Cardium Therapeutics Announces Addition of Vice President
News

Cardium Therapeutics Announces Addition of Vice President

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cardium Therapeutics Announces Addition of Vice President"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cardium Therapeutics Inc., a wholly-owned subsidiary of Aries Ventures Inc., has announced the addition of Jennifer A. Spinella as Vice President - Regulatory Affairs.

Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics said, "We are pleased to welcome Jennifer to Cardium Therapeutics. Jennifer's significant experience in pharmaceutical product development will assist us with the regulatory approval process relating to the commercial development of our lead product, Generx, a DNA-based angiogenic therapeutic."

Ms. Spinella was formerly Director of Regulatory Affairs at Biogen Idec Inc. and was responsible for the regulatory strategy and recent supplemental Biologics License Application (sBLA) for Rituxan® in Rheumatoid Arthritis.

Before joining Biogen Idec in 2003, she was Director of Regulatory Affairs at Idun Pharmaceuticals Inc. and held various regulatory positions at Elan Pharmaceuticals Inc., Chugai Biopharmaceuticals Inc., Dura Pharmaceuticals Inc. and Gensia Pharmaceuticals Inc.

Ms. Spinella earned her B.S. in Medical Technology from the University of Nebraska College of Medicine, Omaha, Nebraska.

Advertisement